|[February 19, 2013]
Precision BioSciences Awarded Patent for Genetically Modifying Cells by the United States Patent Office
RESEARCH TRIANGLE PARK, N.C. --(Business Wire)--
Precision BioSciences, Inc., a leader in the field of genome
engineering, today announced that it has been issued U.S. Patent Number
8,377,674 ("the '674 Patent") by the United States Patent Office. The
issued claims relate to methods used for producing genetically-modified
cells utilizing proprietary genome editing tools. These tools and
resulting cells are made possible via Precision's next-generation genome
engineering technologies, known collectively as the Directed Nuclease
Editor or DNE.
Precision's DNE technology allows for highly precise gene editing with
engineered nucleases, a technique named Method of the Year by Nature
Methods. The '674 Patent greatly strengthens the Company's ability
to protect and capitalize on cells modified with DNE genome editing
nucleases. Precision now controls a growing patent estae consisting of
thirteen issued genome engineering patents in the U.S. and one in Europe.
"Our team is thrilled that the U.S. Patent Office has granted patent
protection to this critical contribution to the genome engineering
field," stated Jeff Smith (News - Alert), co-inventor and Precision BioSciences' Chief
Scientific Officer. "This newly issued patent provides the company with
broad claims to many of the methods used by DNE nucleases to modify
About Precision BioSciences
Precision BioSciences' mission is to continually provide, improve, and
enable the world's most powerful genome engineering technology.
Precision's proprietary Directed Nuclease EditorTM
(DNE) technology enables the production of genome editing enzymes that
can insert, remove, modify, and regulate essentially any gene in
mammalian or plant cells.
Precision BioSciences' vision is to be the conduit through which the
world's greatest genome engineering challenges are solved. Precision has
successfully utilized its DNE technology to create innovative products
in partnerships with many of the world's largest biopharmaceutical,
agbiotech, and animal research firms. Internally, Precision is
developing applications of DNE in biological production and human
therapeutics. For additional information, please visit www.precisionbiosciences.com.
[ Back To Technology News's Homepage ]